Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
Click here for more details
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. We develop therapeutic aerosols to improve and extend the life of patients with peritoneal and pleural cancer.
Our science relies on a growing body of evidence around PIPAC® (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC® provides numerous avenues for research and development in oncology – from re-formulation of existing chemotherapy drugs to next-generation drugs involving siDNA, mRNA, nanomolecules, viruses or immunotherapeutics.
Together with our pharmaceutical clients, we explore the drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.